Azitra, Inc. announces an abstract acceptance for ATR-04-484 clinical trial update at ASCO 2025. They aim to educate oncology professionals about treating EGFR inhibitor-associated rash.

Azitra (NYSE American: AZTR) has initiated dosing in a Phase 1/2 clinical trial for ATR04-484, a topical live biotherapeutic treatment targeting EGFR inhibitor (EGFRi)-associated rash. The condition affects approximately 150,000 people annually in the U.S. and has received FDA Fast Track designation.The multicenter, randomized, double-blind, vehicle-controlled study (NCT06830863) will evaluate ATR04-484's safety and tolerability in adult patients. The treatment addresses a critical medical need, as EGFRi-associated rash affects 50-80% of cancer patients receiving EGFR inhibitor treatments, often leading to cancer treatment interruption or discontinuation.ATR04-484 is derived from a specially engineered Staphylococcus epidermidis strain, designed to reduce IL-36γ and S. aureus levels, which are elevated in affected patients.

Novel biologic ATR04-484 targets severe skin rash that forces cancer patients off treatment. FDA Fast Track designated therapy debuts Phase 1/2 data. Learn more.